Lumos secures follow-on contract with Aptatek Biosciences for development of PKU in-home monitoring device
1 September 2025
Lumos has secured a follow-on contract with Aptatek Biosciences to advance the PheCheck™ in-home monitoring device for phenylketonuria (PKU).
Valued at US$1.5 million, the engagement will progress PheCheck™ through formal verification and validation studies, moving it closer to clinical trials and regulatory submission.
PKU is a rare inherited disorder affecting around 1 in 12,000 newborns. We are proud to support Aptatek in developing an at-home monitoring solution that has the potential to transform disease management for patients and families
Apatek Biosciences CEO, Michael Boyce-Jacino said:
“We are delighted to have selected Lumos once again as our partner in bringing the PheCheck aptamer-based in-home monitoring platform to market. PKU is a challenging condition for patients and families, and a reliable at-home monitoring tool has the potential to transform how it is managed.”
Click to read the ASX release
Valued at US$1.5 million, the engagement will progress PheCheck™ through formal verification and validation studies, moving it closer to clinical trials and regulatory submission.
PKU is a rare inherited disorder affecting around 1 in 12,000 newborns. We are proud to support Aptatek in developing an at-home monitoring solution that has the potential to transform disease management for patients and families
Apatek Biosciences CEO, Michael Boyce-Jacino said:
“We are delighted to have selected Lumos once again as our partner in bringing the PheCheck aptamer-based in-home monitoring platform to market. PKU is a challenging condition for patients and families, and a reliable at-home monitoring tool has the potential to transform how it is managed.”
Click to read the ASX release
